The University of Sheffield research collaboration for EIS oral device
Tuesday 16th June 2020
A research collaboration has been awarded £1m in funding from SBRI Healthcare – an NHS England initiative – to test and develop a pain-free, non-invasive and instantaneous method to detect oral cancer.
- In partnership with Zilico Ltd, the University of Sheffield is working to develop a pain-free, non-invasive and instantaneous method to detect oral cancer
- £1 million in funding has been awarded to the partnership to develop a functional prototype of a new device that uses Electrical Impedance Spectroscopy (EIS) technology for the early detection of cancerous lesions
- The number of cases of oral cancer in the UK has increased by 135 per cent in the past 20 years¹
Once built and tested, the new device could enable doctors to detect oral cancer earlier and more accurately, reducing the need for patients to have invasive biopsies. This in turn could provide better outcomes for patients and significant cost savings for the NHS.
The pioneering device is to be developed with medical device diagnostics company Zilico Ltd - born out of a partnership between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust - using the same patented technology as its ZedScan device, which is now in use in the NHS for the early and non-invasive diagnosis of cervical cancer.
Researchers from the University of Sheffield and Sheffield Teaching Hospitals previously demonstrated that the principle of its electrical impedance spectroscopy (EIS) technology, where normal, precancerous and cancerous tissue can be differentiated according to its electrical properties could be useful for detecting oral cancer. The ‘proof of concept’ study involved 47 patients who were recruited from the Charles Clifford Dental Hospital.
Typically, suspicious oral lesions are inspected and diagnosed visually, but the visual indicators of disease can be misleading or non-apparent in some cases. Many other signs and symptoms of mouth cancer such as constant bad breath and difficulty chewing or swallowing can also be caused by other things than cancer, so a definitive diagnosis can only be made through a biopsy of the tissue.
The new device could enable patients to receive real-time diagnosis at the primary point of their care and the University is now working with Zilico to develop a functional prototype to be assessed and trialled for use in the NHS.
It is anticipated that the prototype will be ready for testing on a group of volunteers, with the aim to progress the project to a full clinical trial in the next 12 months.
Dr Keith Hunter, Professor of Head and Neck Pathology, at the University of Sheffield’s School of Clinical Dentistry and Insigneo Institute for in silico Medicine, said: “Mouth cancer is on the increase in the UK and globally, and we need new tools to be able to diagnose it earlier, as the survival rate for oral cancer patients depends on how early the disease is diagnosed and treated.
“Electrical impedance spectroscopy could help us to diagnose oral cancer earlier and more accurately, even when these cell changes may not be visually apparent. This could reduce the need for biopsies where there is no disease indicated – helping us to reduce patient anxiety and improve patient comfort.
“Hopefully developing less invasive techniques of diagnosing oral cancer will encourage more people to come forward with oral problems.”
Jamie Healey, Lead Clinical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, said: “We have collaborated with Zilico on the technology developments which form the basis of ZedScan for many years, and we are delighted to see that the clinical applications of electrical impedance spectroscopy are broadening, offering the potential for many more patients to benefit from this novel technology.”
To further the scientific evidence and applications for EIS to be used in diagnosing oral cancer, the collaboration with the University of Sheffield’s School of Clinical Dentistry included a diverse range of University departments, including clinicians and researchers from Insigneo, the School of Health and Related Research (ScHARR) and the Department of Computer Science.
Senior Lecturer at the Department of Computer Science and Insigneo member, Dr Dawn Walker, is supervising Dr James Heath a Post Doctoral Research Associate developing cellular and tissue-scale finite element (FE) models to inform the classification of different tissue types based on EIS measurements collected from normal and diseased oral tissue samples in a proof-of-concept study.
She said: “We will build models based on image information from normal and diseased tissues samples, and the results will help us understand the electrical characteristics of different tissue types. Ultimately, this will help us interpret the measurements made with the new device and potentially allow us to further improve its design."
Jim Chilcott, Professor of Healthcare Decision Modelling at ScHARR, said: “Using a whole disease modelling approach we are bringing together the available evidence on oral cancer diagnosis, management and treatment to optimise the design of the new oral device and underpin its diagnostic efficacy.”
“An EIS device for the diagnosing of suspected oral cancer has the potential to make an important contribution to the care and management of the disease, quickly removing uncertainty and anxiety for those without cancer and improving the journey to early treatment for those with cancerous and precancerous lesions.”
Read: Use of Electrical Impedance Spectroscopy to Detect Malignant and Potentially Malignant Oral Lesions
- SBRI Healthcare is an NHS England and NHS Improvement initiative, supported by the Academic Health Science Network (AHSN) and managed by LGC Group. It aims to promote UK economic growth while addressing unmet health needs and enhancing the take up of known best practice. As part of Innovation Health and Wealth, the SBRI Healthcare programme sets industry the challenge in a series of health related competitions which resulted in fully funded development contracts between the awarded company and the NHS.
The University of Sheffield
With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.
A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2018 and for the last eight years has been ranked in the top five UK universities for Student Satisfaction by Times Higher Education.
Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, GlaxoSmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.
For more information, please contact:
Media Relations Officer
0114 222 9859